Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide-Melphalan-Dexamethasone in untreated AL amyloidosis (LEOMEX)
2008-001405-41Phase 2Completed
- Sponsor
- GMIHO mbH
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, melphalan and dexamethasone in light-chain amyloidosis, sponsored by GMIHO mbH. Primary endpoint: Complete remission rate after 6 cycles of L-Mel-Dex. Started Aug 2008; status: completed.
02
Drugs
lenalidomidemelphalandexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2008-001405-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001405-41.